long intergenic non-protein coding RNA 2865Genealiases: []
Q-omics provides the consensus-scored LINC02865 profile across patient tissues and cancer cell-line models. LINC02865 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LINC02865 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, LINC02865 RNA expression shows 6,829 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRP, KIRC, and STAD as cancer lineages where LINC02865 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02865 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02865 survival associations across molecular data types. LINC02865 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02865 RNA expression–survival associations across cancer types. High LINC02865 expression shows unfavorable associations in KIRP, ACC and UVM, but favorable associations in SKCM, LUSC and TGCT. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LINC02865 RNA expression.
This table summarizes LINC02865 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02865. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02865 shows lower tumor expression in LUAD and higher tumor expression in KIRC, HNSC and CHOL. The KIRC box plot shows higher LINC02865 RNA expression in tumor versus normal tissue (log2 FC = +0.038, t-test p < 0.001).
This table shows molecular features associated with LINC02865 in patient tissues and cancer cell lines. In patient samples, LINC02865 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
